Asn-Gly-Arg-modified polydopamine-coated nanoparticles for dual-targeting therapy of brain glioma in rats

Jiangang Hu; Xiang Zhang; Zuhuang Wen; Ying Tan; Ning Huang; Si Cheng; Huzhi Zheng; Yuan Cheng

doi:10.18632/oncotarget.12047

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Asn-Gly-Arg-modified polydopamine-coated nanoparticles for dual-targeting therapy of brain glioma in rats

Jiangang Hu, Xiang Zhang, Zuhuang Wen, Ying Tan, Ning Huang, Si Cheng, Huzhi Zheng _ and Yuan Cheng

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:73681-73696. https://doi.org/10.18632/oncotarget.12047

Metrics: PDF 2320 views | HTML 3574 views | ?

Abstract

Jiangang Hu1,2, Xiang Zhang1,2, Zuhuang Wen3, Ying Tan1, Ning Huang1, Si Cheng4, Huzhi Zheng3, Yuan Cheng1

1Department of Neurosurgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China

2Chongqing Key Laboratory of Ultrasound Molecular Imaging, Institute of Ultrasound Imaging of Chongqing Medical University, Chongqing, 400016, China

3College of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715, China

4Department of Orthopaedics, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

Correspondence to:

Huzhi Zheng, email: [email protected]

Yuan Cheng, email: [email protected]

Keywords: Asn-Gly-Arg, polydopamine, dual-targeting, gliomas

Received: May 29, 2016 Accepted: August 26, 2016 Published: September 15, 2016

ABSTRACT

The blood-brain barrier (BBB) is the major clinical obstacle in the chemotherapeutic management of brain glioma. Here we synthesized a pH-sensitive dual-targeting doxorubicin (DOX) carrier to compromise tumor endothelial cells, enhance BBB transportation, and improve drug accumulation in glioma cells. The drug delivery system was constructed with polydopamine (PDA)-coated mesoporous silica nanoparticles (NPs, MSNs) and the PDA coating was functionalized with Asn-Gly-Arg (NGR), a ligand with specific affinity for cluster of differentiation 13 (CD13). MSN-DOX-PDA-NGR showed a higher intracellular accumulation in primary brain capillary endothelial cells (BCECs) and C6 cells and greater BBB permeability than the non-targeting NPs (MSN-DOX-PDA) did in vitro. Ex vivo and in vivo tests showed that MSN-DOX-PDA-NGR had a higher accumulation in intracranial tumorous tissue than the undecorated NPs did. Furthermore, the antiangiogenesis and antitumor efficacy of MSN-DOX-PDA-NGR were stronger than that of MSN-DOX-PDA. Therefore, these results indicate that the dual-targeting vehicles are potentially useful in brain glioma therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12047

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Asn-Gly-Arg-modified polydopamine-coated nanoparticles for dual-targeting therapy of brain glioma in rats

Abstract